Roche: positive results for fenetbrutinib

(CercleFinance.com) - Roche today announced positive results from the phase II FENopta study of investigational oral fenetbrutinib in adults with relapsing forms of multiple sclerosis (MS).


The study met its primary and secondary endpoints, showing that oral fenetbrutinib significantly reduced magnetic resonance imaging (MRI) markers of disease activity in the brain compared to placebo.

In addition, preclinical data showed that fenobutinib is potent and highly selective, and is the only reversible inhibitor currently in Phase III trials for the treatment of multiple sclerosis.


Copyright (c) 2023 CercleFinance.com. All rights reserved.